Discontinued — last reported Q2 '25
Business Segments · Cost of Revenue
Life Science Member — Cost of Revenue
STERIS Life Science Member — Cost of Revenue decreased by 1.5% to $58.00M in Q2 2025 compared to the prior quarter. Year-over-year, this metric declined by 1.5%, from $58.90M to $58.00M. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ2 2022
Last reportedQ2 2025
Rolls up toTotal Cost of Revenue
How to read this metric
An increase relative to revenue may signal rising input costs, supply chain inefficiencies, or changes in product mix.
Detailed definition
This represents the direct costs associated with producing and delivering the products and services sold within the Life...
Peer comparison
Standard cost of goods sold (COGS) metric for a specific business segment, comparable across manufacturing-heavy peer companies.
Metric ID:
ste_segment_life_science_member_cost_of_revenueHistorical Data
10 periods
| Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q2 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $66.61M | $66.61M | $66.61M | $66.61M | $70.97M | $70.97M | $70.97M | $70.97M | $58.90M | $58.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +6.5% | +0.0% | +0.0% | +0.0% | -17.0% | -1.5% |
| YoY Change | — | — | — | — | +6.5% | +6.5% | +6.5% | +6.5% | -17.0% | -1.5% |
Range$58.00M – $70.97M
CAGR-6.0%
Avg YoY Growth+1.3%
Median YoY Growth+6.5%
Current Streak2 quarters decline
Similar Metrics at Other Companies
Frequently Asked Questions
- What is STERIS's life science member — cost of revenue?
- STERIS (STE) reported life science member — cost of revenue of $58.00M in Q2 2025.
- How has STERIS's life science member — cost of revenue changed year-over-year?
- STERIS's life science member — cost of revenue decreased by 1.5% year-over-year, from $58.90M to $58.00M.
- What does life science member — cost of revenue mean?
- The direct costs incurred to produce the goods and services sold by the Life Science segment.